Trial Profile
A Multicenter, Randomized, Open-Label Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-Injector for the Subcutaneous Self-Injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 10 Aug 2023
Price :
$35
*
At a glance
- Drugs Bimekizumab (Primary)
- Indications Plaque psoriasis
- Focus Adverse reactions; Registrational
- Sponsors UCB Biopharma
- 14 Sep 2020 Status changed from active, no longer recruiting to completed.
- 22 Jun 2020 Planned primary completion date changed from 1 Jul 2020 to 1 Sep 2020.
- 30 Sep 2019 Status changed from recruiting to active, no longer recruiting.